EOLS
Evolus Inc
NASDAQ · Pharmaceuticals
$4.50
+0.09 (+2.04%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 70.51M | 74.40M | 59.96M |
| Net Income | 18.85M | 20.76M | 14.77M |
| EPS | — | — | — |
| Profit Margin | 26.7% | 27.9% | 24.6% |
| Rev Growth | -5.3% | +16.8% | +10.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 122.97M | 118.48M | 106.32M |
| Total Equity | 127.09M | 131.78M | 117.40M |
| D/E Ratio | 0.97 | 0.90 | 0.91 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 37.17M | 38.85M | 31.46M |
| Free Cash Flow | 11.55M | 15.01M | 10.49M |